Related Experiment Video

Updated: May 17, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Lipoprotein(a) and cardiovascular disease in diabetic patients

Qibin Qi1, Lu Qi

  • 1Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA.

Clinical Lipidology
|November 9, 2012
PubMed

Insights

Lipoprotein(a) (Lp[a]) may not increase cardiovascular disease (CVD) risk in diabetic patients, unlike in the general population. Further research is needed to confirm this differential effect of Lp[a] on CVD risk in diabetes.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disorders
  • Lipid Metabolism

Background:

  • Lipoprotein(a) (Lp[a]) is implicated in cardiovascular disease (CVD) risk in the general population.
  • Type 2 diabetes is associated with metabolic abnormalities and increased CVD risk.
  • Previous studies show lower Lp[a] levels in diabetic patients, with inconsistent findings on Lp[a] and CVD risk.

Purpose of the Study:

  • To investigate the role of Lp[a] in CVD risk specifically within diabetic patient cohorts.
  • To clarify the potentially differential impact of Lp[a] on cardiovascular risk between diabetic patients and the general population.

Main Methods:

  • Analysis of Lp[a]-related genetic markers in two diabetic cohorts.
  • Review of existing epidemiological data on Lp[a] and CVD risk in diabetic populations.

Main Results:

  • Lp[a]-related genetic markers did not predict CVD risk in the analyzed diabetic cohorts.
  • Epidemiological studies on Lp[a] and CVD risk in diabetic patients have yielded inconsistent results.

Conclusions:

  • Current evidence suggests Lp[a] may have a different role in cardiovascular risk for diabetic patients compared to the general population.
  • Further prospective studies, Mendelian randomization, and functional studies are required to elucidate the causal relationship between Lp[a] and CVD in Type 2 diabetes.

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...